Courtagen Submits Pre-IDE to FDA for C-reactive Protein Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said it has submitted its first pre-investigational device exemption information package to US regulators for its automated solution for measuring C-reactive proteins in a clinical setting.

In addition to its submission to the US Food and Drug Administration, Courtagen is pursuing a CE Mark for the solution, which is comprised of its Avantra Q400 BioMarker Workstation and the QPDx BioChip.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.